RayzeBio, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $72,120,000.
Profit Margin
| 2020 | 0 | -6.91M | |
|---|---|---|---|
| 2021 | 0 | -29.44M | |
| 2022 | 0 | -68.6M |
RYZB Income Statement (2020 – 2022)
| 2022 | 2021 | 2020 | |
|---|---|---|---|
Revenue | |||
Revenue | 0 | 0 | 0 |
Cost of revenue | 0 | 0 | 0 |
Gross profit | 0 | 0 | 0 |
Operating exp. | |||
Research and development | 61.17M | 33.87M | 5.84M |
Selling and marketing | 0 | 0 | 0 |
Total operating expenses | 72.12M | 39.37M | 6.92M |
Operating income | -72.12M | -39.37M | -6.92M |
Other income (expenses), net | 3.52M | 9.67M | 5K |
Income before tax | -68.6M | -29.44M | -6.91M |
Income tax expense | 0 | -265K | 0 |
Net income | -68.6M | -29.44M | -6.91M |
Earnings per share | |||
Basic EPS | -1.75 | -0.73 | -0.17 |
Diluted EPS | -1.75 | -0.73 | -0.17 |